Similarly, GDF2 mutations may predispose to PAH (Eyries et al., 2019; Gräf et al., 2018; Hodgson et al., 2019; G. Wang et al., 2016; Wang et al., 2019) as well as an “HHT‐like” syndrome characterized by cutaneous telangiectases and AVMs (Liu et al., 2020; Wooderchak‐Donahue et al., 2013). Here, GDF2 is linked to pulmonary arterial hypertension.